Open in Screener

ABEO

Abeona Therapeutics Inc

Aug 15 • 04:00PM ET

7.13

Dollar change -0.10
Percentage change -1.38	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN QURE SRPT SGMO BLUE CLGN ADVM FATE VYGR NTLA

| Held by: IWM VTI VXF SURI IWO VTWO ITOT IWC VFMO VTWG

Index	RUT	P/E	11.30	EPS (ttm)	0.63	Insider Own	11.10%	Shs Outstand	51.25M	Perf Week	13.90%
Market Cap	365.62M	Forward P/E	57.81	EPS next Y	0.12	Insider Trans	-4.84%	Shs Float	45.58M	Perf Month	7.54%
Enterprise Value	163.84M	PEG	-	EPS next Q	-0.26	Inst Own	69.41%	Short Float	18.47%	Perf Quarter	23.14%
Income	57.24M	P/S	914.05	EPS this Y	136.13%	Inst Trans	19.69%	Short Ratio	8.78	Perf Half Y	20.24%
Sales	0.40M	P/B	2.23	EPS next Y	-77.98%	ROA	30.11%	Short Interest	8.42M	Perf YTD	28.01%
Book/sh	3.19	P/C	1.62	EPS next 5Y	-	ROE	48.34%	52W High	7.32 -2.64%	Perf Year	43.17%
Cash/sh	4.40	P/FCF	-	EPS past 3/5Y	58.40% 47.21%	ROIC	31.53%	52W Low	3.93 81.30%	Perf 3Y	71.39%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-695.25%	Volatility	5.33% 4.70%	Perf 5Y	-90.46%
Dividend TTM	-	EV/Sales	409.60	EPS Y/Y TTM	147.55%	Oper. Margin	-18634.00%	ATR (14)	0.32	Perf 10Y	-94.88%
Dividend Ex-Date	-	Quick Ratio	6.65	Sales Y/Y TTM	-100.00%	Profit Margin	14310.50%	RSI (14)	66.57	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.73	EPS Q/Q	749.79%	SMA20	8.38%	Beta	1.67	Target Price	20.07
Payout	-	Debt/Eq	0.15	Sales Q/Q	-	SMA50	13.92%	Rel Volume	1.18	Prev Close	7.23
Employees	136	LT Debt/Eq	0.11	Earnings	Aug 14 BMO	SMA200	23.03%	Avg Volume	958.44K	Price	7.13
IPO	Sep 19, 1980	Option/Short	Yes / Yes	EPS/Sales Surpr.	538.46% -	Trades		Volume	1,154,210	Change	-1.38%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-25	Resumed	Oppenheimer	Outperform	$19
Mar-05-25	Initiated	Oppenheimer	Outperform	$16
Jul-03-24	Initiated	H.C. Wainwright	Buy	$15
May-30-24	Initiated	Stifel	Buy	$21
Nov-11-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$4
Sep-18-20	Initiated	B. Riley FBR	Buy	$5
Feb-10-20	Initiated	SVB Leerink	Outperform	$6
Dec-10-19	Resumed	Cantor Fitzgerald	Neutral	$2 → $4
Aug-15-19	Downgrade	Maxim Group	Buy → Hold
Aug-12-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$29 → $2
Jul-26-19	Downgrade	Mizuho	Buy → Neutral	$17 → $4
Jun-27-19	Initiated	Mizuho	Buy
Oct-12-18	Initiated	Mizuho	Buy	$17
Jun-05-18	Initiated	Seaport Global Securities	Buy	$29
Nov-08-17	Initiated	SunTrust	Buy	$26
Oct-16-17	Reiterated	H.C. Wainwright	Buy	$20 → $30
Oct-11-17	Reiterated	Cantor Fitzgerald	Overweight	$21 → $34
Oct-10-17	Initiated	Citigroup	Buy	$32
Oct-05-17	Reiterated	Maxim Group	Buy	$17 → $35
Sep-15-17	Initiated	RBC Capital Mkts	Outperform	$23

Show Previous Ratings

Aug-14-25 07:38AM	Abeona Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +10.21%
07:30AM	Abeona Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Aug-11-25 06:19AM	Cell Sheet-based Gene Therapy Market Analysis and Forecast, 2025-2035 \| Abeona Therapeutics, CellSeed, J-TEC, and Holostem Lead with First-in-Class Therapies and Strong Commercialization Strategies (GlobeNewswire)
Aug-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-31-25 11:40PM	Abeona Therapeutics, AscellaHealth Partner for Commercialization of ZEVASKYN Gene Therapy (Insider Monkey) -6.32%
10:00AM	Loading…
Jul-29-25 10:00AM	AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients (GlobeNewswire)
Jul-15-25 07:30AM	ZEVASKYN Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area (GlobeNewswire)
Jul-14-25 07:00AM	Bio-Techne's Simple Western Technology Utilized in Recent FDA Approval of ZEVASKYN Cell-Based Gene Therapy (PR Newswire)
Jul-02-25 07:30AM	Abeona Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million (GlobeNewswire) +5.39%
Jul-01-25 07:30AM	Abeona Therapeutics Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy (GlobeNewswire)
07:15AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-30-25 07:30AM	Abeona Therapeutics added to Membership of U.S. Small-cap Russell 2000 Index and Broad-market Russell 3000 Index (GlobeNewswire)
Jun-24-25 07:30AM	Abeona Therapeutics Announces Publication in The Lancet of Phase 3 VIITAL Study Data in Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire)
Jun-02-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-25 08:46AM	Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
07:38AM	Loading…
May-15-25 07:38AM	Abeona Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +7.42%
07:30AM	Abeona Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
May-14-25 08:07AM	UPDATE -- Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
07:30AM	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
07:30AM	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
May-13-25 07:21AM	Abeona secures cash runway with $155m priority review voucher sale (Pharmaceutical Technology)
May-12-25 07:30AM	Abeona Therapeutics Enters into Agreement to Sell Priority Review Voucher for $155 Million (GlobeNewswire) +6.26%
04:38AM	Abeona sells speedy drug review voucher for $155M (BioPharma Dive)
May-07-25 04:59PM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.51%
Apr-30-25 07:16AM	FDA approves Abeonas $3.1m cell therapy for rare skin disease (Pharmaceutical Technology) +23.77%
Apr-29-25 03:06PM	Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy (Benzinga)
06:00AM	U.S. FDA Approves ZEVASKYN (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire)
Apr-27-25 08:30AM	Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken + (Seeking Alpha)
Apr-21-25 10:00AM	Pz-Cel Has Massive Potential For RDEB Patients (Seeking Alpha)
Apr-14-25 07:11AM	Abeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Long-Term Upside (Seeking Alpha) +7.61%
11:39AM	Loading…
Apr-12-25 11:39AM	Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher (Seeking Alpha)
Apr-06-25 08:38AM	Krystal Biotech: Some Uncertainty, Some Value (Seeking Alpha)
Apr-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.51%
Mar-21-25 03:02AM	Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
12:41AM	Q4 2024 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-25 03:21PM	Abeona Therapeutics targets $2B revenue potential for pz-cel amid U.S. launch preparations (SeekingAlpha)
03:20PM	Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:30AM	Abeona Therapeutics Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans (GlobeNewswire)
Mar-04-25 09:00AM	Abeona Therapeutics to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
07:46AM	Abeona Therapeutics announces new employee inducement grants (TipRanks)
Mar-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-31-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-02-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESS Newswire) +6.30%
Nov-15-24 02:06AM	Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-14-24 07:42AM	Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
Nov-12-24 07:30AM	Abeona Therapeutics Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire) -5.05%
Nov-04-24 07:30AM	Abeona Therapeutics Announces Participation in November Investor Conferences (GlobeNewswire)
Nov-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-29-24 07:30AM	Abeona Therapeutics Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration (GlobeNewswire)
Oct-09-24 06:13PM	Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ... (GuruFocus.com)
Oct-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-24 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Sep-02-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-14-24 07:30AM	Abeona Therapeutics Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors (GlobeNewswire)
Aug-13-24 07:30AM	Abeona Therapeutics Announces Favorable Medicare Reimbursement Decisions for Pz-cel (GlobeNewswire)
Aug-12-24 07:37AM	Abeona Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +11.99%
07:30AM	Abeona Therapeutics Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission (GlobeNewswire)
Aug-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-11-24 07:30AM	Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications (GlobeNewswire)
Jul-08-24 07:30AM	Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum (GlobeNewswire) +5.73%
Jun-21-24 03:08AM	Insider Sale: Director Christine Silverstein Sells Shares of Abeona Therapeutics Inc (ABEO) (GuruFocus.com)
Jun-03-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-24 07:30AM	Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-24 03:01AM	Abeona Therapeutics Inc (ABEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ... (GuruFocus.com)
02:17AM	Q1 2024 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-24 12:53PM	ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +12.14%
07:43AM	Abeona Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress (GlobeNewswire)
May-07-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-03-24 11:19AM	Abeona Therapeutics Prices $75 Million Securities Offering; Shares Rise (MT Newswires) +13.02%
07:30AM	Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Apr-23-24 02:04PM	Top Midday Decliners (MT Newswires) -53.67%
08:53AM	Why Is Abeona Therapeutics (ABEO) Stock Down 45% Today? (InvestorPlace)
07:39AM	Top Premarket Decliners (MT Newswires)
07:09AM	FDA rejects Abeona cell therapy, asks for more manufacturing data (BioPharma Dive)
Apr-22-24 05:58PM	Abeona Therapeutics Shares Slump After Plans to Reapply for Pz-cel Drug Approval (MT Newswires)
04:27PM	UPDATE 1-US FDA declines to approve Abeona's skin disorder treatment (Reuters)
04:14PM	US FDA declines to approve Abeona's skin disorder treatment (Reuters)
04:05PM	Abeona Therapeutics Provides Regulatory Update on Pz-cel (GlobeNewswire)
Apr-01-24 08:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.48%
Mar-19-24 06:53AM	ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +8.30%
05:31AM	Abeona Therapeutics Inc (ABEO) Reports Full Year 2023 Financial Results (GuruFocus.com)
Mar-18-24 07:30AM	Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections (GlobeNewswire) -19.00%
Mar-05-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.32%
Feb-15-24 05:52AM	Steven Cohen's Firm Increases Stake in Abeona Therapeutics Inc (GuruFocus.com) +5.53%
Feb-01-24 04:05PM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.65%
07:30AM	Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA) (GlobeNewswire)
Jan-08-24 07:30AM	Abeona Therapeutics Announces $50 Million Credit Facility (GlobeNewswire)
Dec-15-23 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-27-23 07:30AM	Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA) (GlobeNewswire) +11.60%
Nov-17-23 10:09AM	Abeona Therapeutics Inc. (NASDAQ:ABEO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 04:29AM	Q3 2023 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -5.56%
Nov-13-23 12:23PM	Abeona Therapeutics Inc (ABEO) Reports Q3 2023 Financial Results and Advances in Commercial ... (GuruFocus.com) +10.02%
07:41AM	Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments (GlobeNewswire)
Nov-01-23 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-26-23 07:30AM	Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire) +9.84%

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Crombez Eric	Director	Aug 14 '25	Sale	6.93	4,718	32,683	42,427	Aug 15 04:30 PM
Vazzano Joseph Walter	Chief Financial Officer	Aug 15 '25	Sale	7.36	15,000	110,358	462,666	Aug 15 04:30 PM
Vazzano Joseph Walter	Officer	Aug 15 '25	Proposed Sale	7.36	15,000	110,358		Aug 15 04:15 PM
Vazzano Joseph Walter	Chief Financial Officer	Jul 22 '25	Sale	6.64	1,502	9,975	477,666	Jul 22 04:15 PM
Vazzano Joseph Walter	Officer	Jul 22 '25	Proposed Sale	6.64	1,502	9,975		Jul 22 04:11 PM
Silverstein Christine Berni	Director	Jul 09 '25	Sale	5.86	13,093	76,669	120,479	Jul 10 04:30 PM
Seshadri Vishwas	Chief Executive Officer	Jul 09 '25	Sale	5.86	69,420	406,503	1,234,341	Jul 10 04:30 PM
Vazzano Joseph Walter	Chief Financial Officer	Jul 09 '25	Sale	5.86	25,411	148,799	479,168	Jul 10 04:30 PM
Wuchterl Donald A.	Director	Jul 08 '25	Sale	5.82	5,176	30,147	145,436	Jul 10 04:30 PM
Charles Faith L.	Director	Jul 09 '25	Sale	5.86	10,738	62,879	139,094	Jul 10 04:30 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Jul 09 '25	Sale	5.86	17,428	102,053	360,817	Jul 10 04:30 PM
Alvino Mark	Director	Jul 09 '25	Sale	5.86	13,093	76,669	77,252	Jul 10 04:30 PM
Vazzano Joseph Walter	Officer	Jul 09 '25	Proposed Sale	5.86	25,335	148,354		Jul 09 04:55 PM
Seshadri Vishwas	Officer	Jul 09 '25	Proposed Sale	5.86	69,215	405,302		Jul 09 04:52 PM
O'Malley Brendan M.	Officer	Jul 09 '25	Proposed Sale	5.86	17,376	101,749		Jul 09 04:48 PM
Charles Faith L.	Director	Jul 09 '25	Proposed Sale	5.86	10,706	62,691		Jul 09 04:45 PM
Silverstein Christine Berni	Director	Jul 09 '25	Proposed Sale	5.86	13,054	76,440		Jul 09 04:40 PM
Alvino Mark	Director	Jul 09 '25	Proposed Sale	5.86	13,054	76,440		Jul 09 04:36 PM
Wuchterl Donald A.	Director	Jul 08 '25	Proposed Sale	5.82	5,176	30,147		Jul 08 04:06 PM
Vazzano Joseph Walter	Chief Financial Officer	Jun 06 '25	Sale	6.76	17,795	120,294	491,246	Jun 06 06:04 PM
Seshadri Vishwas	Chief Executive Officer	Jun 06 '25	Sale	6.76	50,676	342,570	1,303,761	Jun 06 06:00 PM
O'Malley Brendan M.	SVP, General Counsel	Jun 06 '25	Sale	6.76	10,470	70,777	378,245	Jun 06 05:56 PM
Vazzano Joseph Walter	Officer	Jun 06 '25	Proposed Sale	6.76	17,795	120,314		Jun 06 04:13 PM
O'Malley Brendan M.	Director	Jun 06 '25	Proposed Sale	6.76	10,470	70,789		Jun 06 04:12 PM
Seshadri Vishwas	Officer	Jun 06 '25	Proposed Sale	6.76	50,676	342,626		Jun 06 04:11 PM
Alvino Mark	Director	May 27 '25	Sale	6.38	2,000	12,760	90,435	May 27 07:57 PM
Alvino Mark	Director	May 27 '25	Proposed Sale	6.38	2,000	12,762		May 27 04:40 PM
Alvino Mark	Director	May 16 '25	Sale	5.68	8,000	45,440	92,435	May 16 05:23 PM
Alvino Mark	Director	May 16 '25	Proposed Sale	5.68	8,000	45,423		May 16 04:07 PM
Seshadri Vishwas	Chief Executive Officer	Mar 31 '25	Sale	4.78	25,000	119,500	1,355,322	Mar 31 07:17 PM
Seshadri Vishwas	Officer	Mar 31 '25	Proposed Sale	4.78	25,000	119,560		Mar 31 04:08 PM
Alvino Mark	Director	Jan 29 '25	Sale	5.38	4,000	21,520	64,334	Jan 31 04:30 PM
Alvino Mark	Officer	Jan 29 '25	Proposed Sale	5.41	4,000	21,640		Jan 29 04:03 PM
Alvino Mark	Director	Jan 21 '25	Sale	5.10	4,000	20,400	68,334	Jan 21 04:30 PM
Alvino Mark	Officer	Jan 21 '25	Proposed Sale	5.22	4,000	20,880		Jan 21 04:05 PM

Dollar change +0.68
Percentage change 2.34	%

RARE Ultragenyx Pharmaceutical Inc daily Stock Chart

Peers: BIIB VRTX ALNY BMRN AMGN REGN IONS CRSP NBIX PBYI

| Held by: VTI VB VXF VBK XBI IWP IBB SCHA IWF VHT

Index	-	P/E	-	EPS (ttm)	-5.53	Insider Own	6.63%	Shs Outstand	96.18M	Perf Week	7.81%
Market Cap	2.86B	Forward P/E	-	EPS next Y	-3.64	Insider Trans	-2.51%	Shs Float	89.64M	Perf Month	8.32%
Enterprise Value	3.25B	PEG	-	EPS next Q	-1.23	Inst Own	98.06%	Short Float	8.52%	Perf Quarter	-14.78%
Income	-532.93M	P/S	4.69	EPS this Y	20.72%	Inst Trans	5.22%	Short Ratio	4.05	Perf Half Y	-31.78%
Sales	610.16M	P/B	18.88	EPS next Y	26.95%	ROA	-36.44%	Short Interest	7.64M	Perf YTD	-29.43%
Book/sh	1.57	P/C	5.76	EPS next 5Y	45.72%	ROE	-182.60%	52W High	60.37 -50.82%	Perf Year	-42.68%
Cash/sh	5.15	P/FCF	-	EPS past 3/5Y	2.09% 2.45%	ROIC	-55.60%	52W Low	25.81 15.03%	Perf 3Y	-43.08%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	16.82% 40.12%	Gross Margin	79.51%	Volatility	2.98% 4.26%	Perf 5Y	-65.13%
Dividend TTM	-	EV/Sales	5.33	EPS Y/Y TTM	24.18%	Oper. Margin	-82.78%	ATR (14)	1.32	Perf 10Y	-72.92%
Dividend Ex-Date	-	Quick Ratio	2.30	Sales Y/Y TTM	26.77%	Profit Margin	-87.34%	RSI (14)	51.57	Recom	1.19
Dividend Gr. 3/5Y	- -	Current Ratio	2.45	EPS Q/Q	23.19%	SMA20	6.49%	Beta	0.21	Target Price	85.05
Payout	-	Debt/Eq	5.84	Sales Q/Q	13.24%	SMA50	-8.61%	Rel Volume	0.72	Prev Close	29.01
Employees	1294	LT Debt/Eq	5.34	Earnings	Aug 05 AMC	SMA200	-24.39%	Avg Volume	1.88M	Price	29.69
IPO	Jan 31, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.81% 2.77%	Trades		Volume	1,349,999	Change	2.34%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-28-25	Resumed	H.C. Wainwright	Buy	$80
May-28-25	Initiated	William Blair	Outperform
Jun-06-24	Upgrade	Goldman	Neutral → Buy	$56 → $67
Apr-22-24	Initiated	RBC Capital Mkts	Outperform	$77
Dec-08-23	Initiated	Wells Fargo	Overweight	$72
Jun-14-23	Resumed	Credit Suisse	Outperform	$96
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform	$60 → $80
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight	$114
Jan-18-23	Resumed	Canaccord Genuity	Buy	$90
Dec-30-22	Resumed	H.C. Wainwright	Buy	$82
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform	$50
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$50
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line	$95 → $60
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform	$99 → $105
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight	$132
Sep-30-21	Initiated	H.C. Wainwright	Buy	$106
Aug-19-21	Initiated	UBS	Sell	$73
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy	$162
Jun-04-21	Resumed	Robert W. Baird	Neutral	$109

Show Previous Ratings

Aug-06-25 11:43AM	Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
03:29AM	Ultragenyx Pharmaceutical Inc (RARE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Aug-05-25 05:30PM	Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:06PM	Ultragenyx: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
03:32PM	Loading…
Aug-04-25 03:32PM	Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory (Insider Monkey)
Jul-31-25 04:05PM	Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome (GlobeNewswire)
11:35AM	Ultragenyx Pharmaceutical Inc. (RARE) Gets FDA CRL for UX111, Vows Quick Resubmission (Insider Monkey)
10:00AM	Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline (Zacks)
Jul-30-25 08:30AM	Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
Jul-24-25 11:09AM	BioHarvest Sciences Inc. (BHST) Surges 5.6%: Is This an Indication of Further Gains? (Zacks)
Jul-22-25 10:05AM	FDA Rejects Replimunes Skin Cancer Treatment, Shares Sink (Bloomberg)
Jul-18-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-17-25 10:38AM	Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Jul-16-25 09:38AM	William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
07:00AM	Loading…
07:00AM	New Pedestrian Access from Inner Belt to East Somerville MBTA Station Now Open to the Public (PR Newswire)
Jul-15-25 08:28AM	Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA (Zacks) -6.94%
05:46AM	Health Canada extends Evkeeza approval for children with HoFH (Pharmaceutical Technology)
Jul-14-25 04:24PM	Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejection (Investor's Business Daily)
08:00AM	Health Canada Extends the Approval of Evkeeza (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
07:53AM	FDA rejects Ultragenyx gene therapy over manufacturing concerns (BioPharma Dive)
07:34AM	Ultragenyx receives complete response letter for UX111 BLA (Pharmaceutical Technology)
Jul-13-25 03:12PM	Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light (Insider Monkey)
Jul-11-25 04:30PM	Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
07:51AM	Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update (BioPharma Dive)
Jul-10-25 04:17PM	Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Disease (Investor's Business Daily) -25.11%
10:37AM	Biotech Stock Ultragenyx Is Falling on Unsatisfying Trial Update (Barrons.com)
10:17AM	RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End (Zacks)
09:19AM	Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains? (Zacks)
07:52AM	Kellogg shares soar on buyout talk, and other early market movers (MarketWatch)
04:05PM	Loading…
Jul-09-25 04:05PM	Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis (GlobeNewswire) +5.12%
12:55AM	Ultragenyx's GTX-102 Receives FDA Breakthrough Therapy Designation for Angelman Syndrome (Insider Monkey)
Jun-30-25 11:40AM	RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome (Zacks)
Jun-27-25 08:00AM	Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome (GlobeNewswire)
Jun-20-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-05-25 11:31AM	Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-03-25 05:00PM	Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-20-25 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.19%
May-14-25 04:30PM	Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report (GlobeNewswire)
May-08-25 10:25AM	Ultragenyx price target lowered to $100 from $140 at Truist (TipRanks) +7.66%
May-07-25 05:00PM	Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference (GlobeNewswire)
12:15PM	Q1 2025 Ultragenyx Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
10:45AM	Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
03:23AM	Ultragenyx Pharmaceutical Inc (RARE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
May-06-25 11:32PM	Ultragenyx projects $640M-$670M revenue for 2025 with strong product growth (Seeking Alpha) -9.80%
11:31PM	Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:00PM	Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:10PM	Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
May-05-25 09:13AM	5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates (Zacks)
Apr-30-25 05:00PM	Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
Apr-29-25 10:01AM	Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-24-25 10:01AM	Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-22-25 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-21-25 10:00AM	Pz-Cel Has Massive Potential For RDEB Patients (Seeking Alpha)
Apr-16-25 09:49AM	Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline (Seeking Alpha)
Apr-13-25 08:50PM	Ultragenyx Pharmaceutical (RARE): Among Billionaire Stanley Druckenmiller's Top Stock Picks with Huge Upside Potential (Insider Monkey)
Apr-10-25 09:30AM	Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? (Zacks)
Mar-29-25 04:20PM	Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy (Insider Monkey)
Mar-19-25 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-18-25 09:16AM	Ultragenyx price target lowered to $115 from $140 at Piper Sandler (TipRanks)
Feb-24-25 04:30PM	Ultragenyx to Participate at Investor Conferences in March (GlobeNewswire)
Feb-19-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-18-25 08:00AM	Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Feb-14-25 09:48AM	Q4 2024 Ultragenyx Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
02:23AM	Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Feb-13-25 04:19PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update (GlobeNewswire)
Feb-06-25 04:30PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update (GlobeNewswire)
08:21AM	Ultragenyx announces new data on UX111 AV gene therapy (TipRanks)
Feb-05-25 08:00AM	Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS (GlobeNewswire)
Jan-17-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:14AM	Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential (Insider Monkey)
Jan-15-25 02:05PM	Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside (Benzinga)
Jan-12-25 11:00AM	Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones (GlobeNewswire)
Jan-06-25 04:30PM	Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:07AM	Ultragenyxs Evkeeza secures EU approval for young children with rare cholesterol disorder (Pharmaceutical Technology)
02:00AM	European Commission (EC) Extends the Approval of Evkeeza (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Dec-20-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
03:00AM	NHS England Rolls Out Evkeeza (evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH) (GlobeNewswire)
Dec-19-24 04:05PM	Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome (GlobeNewswire)
08:00AM	Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Nov-26-24 04:30PM	Ultragenyx to Participate in Investor Conferences in December (GlobeNewswire)
Nov-20-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-24 10:30AM	Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit (GlobeNewswire)
Nov-06-24 02:27AM	Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ... (GuruFocus.com)
Nov-05-24 04:11PM	Ultragenyx: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Nov-01-24 09:16AM	What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity? (Insider Monkey)
Oct-29-24 04:05PM	Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Oct-18-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-07-24 08:00AM	Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta (GlobeNewswire)
Oct-03-24 04:30PM	Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease (GlobeNewswire)
Sep-26-24 08:00AM	Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting (GlobeNewswire)
Sep-18-24 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 01:07AM	Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 04:30PM	Ultragenyx to Participate in Investor Conferences in September (GlobeNewswire)
Aug-21-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.62%
Aug-06-24 10:45AM	3 Genomics Stocks That May Transform Personalized Medicine (InvestorPlace)

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sanders Corazon (Corsee) D.	Director	Jun 20 '25	Sale	37.39	2,405	89,923	15,344	Jun 23 01:50 PM
CORAZON D. SANDERS	Director	Jun 20 '25	Proposed Sale	37.39	2,405	89,923		Jun 20 04:02 PM
Crombez Eric	EVP and Chief Medical Officer	May 05 '25	Sale	39.24	520	20,405	71,530	May 05 07:18 PM
Crombez Eric	EVP and Chief Medical Officer	Apr 21 '25	Sale	35.11	242	8,497	71,680	May 05 07:18 PM
Horn Howard	Chief Financial Officer	Mar 06 '25	Sale	40.40	1,785	72,114	106,169	Mar 10 12:53 PM
Kassberg Thomas Richard	CBO & EVP	Mar 03 '25	Sale	42.10	6,028	253,779	265,238	Mar 04 08:19 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 03 '25	Sale	42.10	12,846	540,817	75,287	Mar 04 08:18 PM
Crombez Eric	EVP and Chief Medical Officer	Mar 03 '25	Sale	42.10	8,945	376,584	71,922	Mar 04 08:16 PM
Pinion John Richard	See Remarks	Mar 03 '25	Sale	42.10	14,439	607,882	107,766	Mar 04 08:12 PM
KAKKIS EMIL D	President & CEO	Mar 03 '25	Sale	42.10	73,434	3,091,571	641,731	Mar 04 08:10 PM
KAKKIS EMIL D	President & CEO	Feb 28 '25	Sale	42.48	25,000	1,062,000	2,158,985	Mar 04 08:10 PM
Harris Erik	EVP & Chief Commercial Officer	Mar 03 '25	Sale	42.10	15,103	635,836	87,855	Mar 04 08:06 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Mar 03 '25	Sale	42.10	967	40,711	50,265	Mar 04 08:00 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Feb 27 '25	Sale	42.88	2,990	128,224	54,991	Mar 03 01:58 PM
KAKKIS EMIL D	Officer	Feb 28 '25	Proposed Sale	42.48	25,000	1,062,100		Feb 28 04:11 PM
Parschauer Karah Herdman	Officer	Feb 27 '25	Proposed Sale	42.88	2,990	128,215		Feb 27 05:08 PM
KAKKIS EMIL D	President & CEO	Dec 30 '24	Sale	42.23	11,727	495,231	2,183,985	Dec 31 02:05 PM
KAKKIS EMIL D	Officer	Dec 30 '24	Proposed Sale	42.23	11,727	495,264		Dec 30 04:32 PM
KAKKIS EMIL D	President & CEO	Dec 10 '24	Sale	50.00	8,273	413,650	2,195,712	Dec 11 06:44 PM
KAKKIS EMIL D	Officer	Dec 10 '24	Proposed Sale	50.00	8,273	413,650		Dec 10 04:12 PM
Horn Howard	Chief Financial Officer	Oct 10 '24	Sale	52.76	7,465	393,853	92,301	Oct 11 04:48 PM
KAKKIS EMIL D	President & CEO	Sep 03 '24	Sale	55.85	20,000	1,117,000	2,223,985	Sep 05 11:53 AM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 03 '24	Sale	56.19	91	5,113	41,551	Sep 05 11:50 AM
KAKKIS EMIL D	Officer	Sep 03 '24	Proposed Sale	55.85	20,000	1,117,096		Sep 03 04:40 PM

ABEO

Abeona Therapeutics Inc

RARE

Ultragenyx Pharmaceutical Inc

Upgrade your FINVIZ experience